Compare STKL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKL | KALV |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.0M | 757.7M |
| IPO Year | 1999 | 2014 |
| Metric | STKL | KALV |
|---|---|---|
| Price | $6.46 | $18.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.83 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.8M | 554.3K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 186.67 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $817,715,000.00 | $50,000,000.00 |
| Revenue This Year | $13.82 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $49.81 | ★ N/A |
| Revenue Growth | 12.99 | ★ 495.66 |
| 52 Week Low | $3.32 | $9.83 |
| 52 Week High | $6.94 | $19.00 |
| Indicator | STKL | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 76.35 | 71.25 |
| Support Level | $5.73 | $14.45 |
| Resistance Level | $6.53 | $19.00 |
| Average True Range (ATR) | 0.05 | 0.72 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 44.83 | 94.70 |
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own propriety brands, including SOWN, Dream and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada and Others, out of which it derives maximum revenue from U.S.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.